In the past, big pharmaceutical manufacturers and their generic drug-maker counterparts have regularly engaged in battles before Congress. They’ve fought over the parameters of the patent challenge process, for example, and whether generics have the right to use certain “biologic” medicines.

Now, however, the two industries have joined forces for a different sort of lobbying battle.